atipamezole
Trade name: Antisedan
Atipamezole, sold under the brand name Antisedan among others, is a synthetic α2 adrenergic receptor antagonist used for the reversal of the sedative and analgesic effects of dexmedetomidine and medetomidine in dogs. Its reversal effect works by competing with the sedative for α2-adrenergic receptors and displacing them. It is mainly used in veterinary medicine, and while it is only licensed for dogs and for intramuscular use, it has been used intravenously, as well as in cats and other animals. There is a low rate of side effects, largely due to atipamezole's high specificity for the α2-adrenergic receptor. Atipamezole has a very quick onset, usually waking an animal up within 5 to 10 minutes. — Wikipedia
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Earliest trial started Sep 1, 2011 (NCT01435213)
Timeline
2010s
- Jan 1, 2011
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
Chemistry & pharmacology
SMILES
CCC1(c2c[nH]cn2)Cc2ccccc2C1- Mol. weight
- 212.3 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- Yes
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaAtipamezole ↗
- ChEMBLCHEMBL353972 ↗
Also known as
- 1h-imidazole, 4-(2-ethyl-2,3-dihydro-1h-inden-2-yl)-
- antipamezole
- antisedan
- antisedan
- atipamezole
- atipamezole
- atipamezole
- atipamezole
- mpv 1248
- mpv-1248
- mpv-1248
- mpv-1248
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04942340 | Phase 1 | Apr 30, 2022 | University of Chicago |
| NCT01435213 | Phase 1 | Sep 1, 2011 | Orion Corporation, University of Turku |
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Orion Corporation | For profit | 1 | 0 | 1 | 2011 |
| University of Chicago | Academic/Hospital | 1 | 1 | 1 | 2022 |
| University of Turku | Academic/Hospital | 1 | 1 | 1 | 2011 |